Macrocyclic Compounds Inhibit Mutant EGFR Kinase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic methods for treating EGFR-driven cancers, such as non-small cell lung cancer with mutant EGFR, face challenges due to resistance and limited efficacy of existing tyrosine kinase inhibitors.
Innovation Solution
Development of novel macrocyclic compounds that act as potent inhibitors of EGFR, including mutant forms, to effectively target and inhibit the EGFR pathway, potentially overcoming resistance and improving treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing tyrosine kinase inhibitors are used to treat EGFR-driven cancers, then initial clinical responses are achieved, but resistance develops leading to treatment failure
Solution Approach 1:
The patent modifies the chemical structure of tyrosine kinase inhibitors by changing molecular parameters such as substituting specific hydrogen atoms with fluorine, chlorine, or other groups, and altering the core heterocyclic structure. These parameter changes create new compounds with improved binding affinity and resistance to EGFR mutations that cause treatment failure in standard therapies.
Solution Approach 2:
The invention develops composite molecular structures combining multiple functional groups and heterocyclic systems into a single inhibitor molecule. These composite structures are designed to simultaneously interact with multiple residues in the EGFR kinase domain, creating more robust inhibition that overcomes resistance mechanisms.
2Reliability
If tyrosine kinase inhibitor therapies are administered, then EGFR signaling is inhibited, but mutations in EGFR confer resistance to the therapy
Solution Approach 1:
The patent designs inhibitors with multi-functional binding modes that can accommodate various EGFR mutant forms. The molecular structure includes multiple interaction points that can adapt to different mutation states of EGFR, making the inhibitor effective across a broader range of genetic variations rather than being specific to one mutant type.
Solution Approach 2:
The inhibitor molecule is segmented into distinct functional domains: a core heterocyclic structure for ATP binding, substituent groups for selective interactions with EGFR residues, and linkers that provide flexibility. This segmentation allows each part to independently adapt to different mutation contexts while maintaining overall binding effectiveness.
Data Source
AI summary
Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).